Tumor hypoxia: A target for selective cancer therapy
Tumor hypoxia has been considered to be a potential therapeutic problem because it renders solid tumors more resistant to sparsely ionizing radiation (IR) and chemotherapeutic drugs. Moreover, recent laboratory and clinical data have shown that tumor hypoxia is also associated with a more malignant...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2003-12, Vol.94 (12), p.1021-1028 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1028 |
|---|---|
| container_issue | 12 |
| container_start_page | 1021 |
| container_title | Cancer science |
| container_volume | 94 |
| creator | Kizaka‐Kondoh, Shinae Inoue, Masahiro Harada, Hiroshi Hiraoka, Masahiro |
| description | Tumor hypoxia has been considered to be a potential therapeutic problem because it renders solid tumors more resistant to sparsely ionizing radiation (IR) and chemotherapeutic drugs. Moreover, recent laboratory and clinical data have shown that tumor hypoxia is also associated with a more malignant phenotype and poor survival in patients suffering from various solid tumors. Therefore, selective targeting of hypoxic tumor cells has been explored, and since severe hypoxia (pO2 |
| doi_str_mv | 10.1111/j.1349-7006.2003.tb01395.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11160235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71439832</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6561-470a733d640c7433aaba0916136118853b83483655ab8cf04dbf10a6f6e5ccf03</originalsourceid><addsrcrecordid>eNqVkU1v1DAQhi0Eoh_wF6qoiN4SPBnbcXpBq1U_kCpxoJytidfpZpVNtnZSdv89Xhp1oTd88cc883pmXsbOgWcQ15dVBijKtOBcZTnnmA0VByxltn3Djl9Cb_-ci7TkmB-xkxBWEVWiFO_ZEQilcg7ymIn7cd37ZLnb9NuGLpNZMpB_cENSx9fgWmeH5sklljrrfDIsnafN7gN7V1Mb3MdpP2U_r6_u57fp3febb_PZXWqVVJCKglOBuFCC20IgElXES1CACkBriZVGoVFJSZW2NReLqgZOqlZO2njHU_b1WXczVmu3sK4bPLVm45s1-Z3pqTH_RrpmaR76JxOnpHiOMipcTAq-fxxdGMy6Cda1LXWuH4MpQGCpMY_gp1fgqh99F7szOZZlofMIRerymbK-D8G7-qUW4PtPwazM3gCzN8DsvTGTN2Ybk8_-7uaQOpkRgc8TQMFSW_s49CYcOKkF17o4jOVX07rdf5Rg5rMfwHPA34v_qjI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399782323</pqid></control><display><type>article</type><title>Tumor hypoxia: A target for selective cancer therapy</title><source>Wiley Online Library Open Access</source><creator>Kizaka‐Kondoh, Shinae ; Inoue, Masahiro ; Harada, Hiroshi ; Hiraoka, Masahiro</creator><creatorcontrib>Kizaka‐Kondoh, Shinae ; Inoue, Masahiro ; Harada, Hiroshi ; Hiraoka, Masahiro</creatorcontrib><description>Tumor hypoxia has been considered to be a potential therapeutic problem because it renders solid tumors more resistant to sparsely ionizing radiation (IR) and chemotherapeutic drugs. Moreover, recent laboratory and clinical data have shown that tumor hypoxia is also associated with a more malignant phenotype and poor survival in patients suffering from various solid tumors. Therefore, selective targeting of hypoxic tumor cells has been explored, and since severe hypoxia (pO2<0.33%, 2.5 mmHg) does not occur in normal tissue, tumor hypoxia could be exploited for therapeutic advantage. However, the following three characteristics of hypoxic tumor regions present obstacles in targeting hypoxic cells. First, it is difficult to deliver a sufficient amount of drug to a region that is remote from blood vessels. Second, one must specifically target hypoxic tumor cells while sparing normal well‐oxygenated tissue from damage. Finally, the severely hypoxic tumor cells to be attacked have often stopped dividing. Therefore, high delivery efficiency, high specificity and selective cytotoxicity are all necessary to target and combat hypoxic tumor cells. The current review describes progress on the biological aspects of tumor hypoxia and provides a compilation of the recent molecular approaches used to target hypoxic tumors. These approaches include our work with a unique hypoxia‐targeting protein drug, TOP3, with which we have sought to address the above three difficulties.</description><identifier>ISSN: 1347-9032</identifier><identifier>ISSN: 1349-7006</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/j.1349-7006.2003.tb01395.x</identifier><identifier>PMID: 14662015</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Blood vessels ; Cancer therapies ; Cell Hypoxia ; Cytotoxicity ; Gene Expression ; Genetic Therapy - methods ; Humans ; Hypoxia ; Hypoxia-Inducible Factor 1 ; Ionizing radiation ; Medical sciences ; Neoplasms - blood supply ; Neoplasms - therapy ; Phenotypes ; Recombinant Fusion Proteins - therapeutic use ; Review ; Solid tumors ; Tumor cells ; Tumors</subject><ispartof>Cancer science, 2003-12, Vol.94 (12), p.1021-1028</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright John Wiley & Sons, Inc. Dec 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6561-470a733d640c7433aaba0916136118853b83483655ab8cf04dbf10a6f6e5ccf03</citedby><cites>FETCH-LOGICAL-c6561-470a733d640c7433aaba0916136118853b83483655ab8cf04dbf10a6f6e5ccf03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160235/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160235/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1349-7006.2003.tb01395.x$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15840887$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14662015$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kizaka‐Kondoh, Shinae</creatorcontrib><creatorcontrib>Inoue, Masahiro</creatorcontrib><creatorcontrib>Harada, Hiroshi</creatorcontrib><creatorcontrib>Hiraoka, Masahiro</creatorcontrib><title>Tumor hypoxia: A target for selective cancer therapy</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>Tumor hypoxia has been considered to be a potential therapeutic problem because it renders solid tumors more resistant to sparsely ionizing radiation (IR) and chemotherapeutic drugs. Moreover, recent laboratory and clinical data have shown that tumor hypoxia is also associated with a more malignant phenotype and poor survival in patients suffering from various solid tumors. Therefore, selective targeting of hypoxic tumor cells has been explored, and since severe hypoxia (pO2<0.33%, 2.5 mmHg) does not occur in normal tissue, tumor hypoxia could be exploited for therapeutic advantage. However, the following three characteristics of hypoxic tumor regions present obstacles in targeting hypoxic cells. First, it is difficult to deliver a sufficient amount of drug to a region that is remote from blood vessels. Second, one must specifically target hypoxic tumor cells while sparing normal well‐oxygenated tissue from damage. Finally, the severely hypoxic tumor cells to be attacked have often stopped dividing. Therefore, high delivery efficiency, high specificity and selective cytotoxicity are all necessary to target and combat hypoxic tumor cells. The current review describes progress on the biological aspects of tumor hypoxia and provides a compilation of the recent molecular approaches used to target hypoxic tumors. These approaches include our work with a unique hypoxia‐targeting protein drug, TOP3, with which we have sought to address the above three difficulties.</description><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood vessels</subject><subject>Cancer therapies</subject><subject>Cell Hypoxia</subject><subject>Cytotoxicity</subject><subject>Gene Expression</subject><subject>Genetic Therapy - methods</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Hypoxia-Inducible Factor 1</subject><subject>Ionizing radiation</subject><subject>Medical sciences</subject><subject>Neoplasms - blood supply</subject><subject>Neoplasms - therapy</subject><subject>Phenotypes</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Review</subject><subject>Solid tumors</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>1347-9032</issn><issn>1349-7006</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqVkU1v1DAQhi0Eoh_wF6qoiN4SPBnbcXpBq1U_kCpxoJytidfpZpVNtnZSdv89Xhp1oTd88cc883pmXsbOgWcQ15dVBijKtOBcZTnnmA0VByxltn3Djl9Cb_-ci7TkmB-xkxBWEVWiFO_ZEQilcg7ymIn7cd37ZLnb9NuGLpNZMpB_cENSx9fgWmeH5sklljrrfDIsnafN7gN7V1Mb3MdpP2U_r6_u57fp3febb_PZXWqVVJCKglOBuFCC20IgElXES1CACkBriZVGoVFJSZW2NReLqgZOqlZO2njHU_b1WXczVmu3sK4bPLVm45s1-Z3pqTH_RrpmaR76JxOnpHiOMipcTAq-fxxdGMy6Cda1LXWuH4MpQGCpMY_gp1fgqh99F7szOZZlofMIRerymbK-D8G7-qUW4PtPwazM3gCzN8DsvTGTN2Ybk8_-7uaQOpkRgc8TQMFSW_s49CYcOKkF17o4jOVX07rdf5Rg5rMfwHPA34v_qjI</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Kizaka‐Kondoh, Shinae</creator><creator>Inoue, Masahiro</creator><creator>Harada, Hiroshi</creator><creator>Hiraoka, Masahiro</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>John Wiley & Sons, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200312</creationdate><title>Tumor hypoxia: A target for selective cancer therapy</title><author>Kizaka‐Kondoh, Shinae ; Inoue, Masahiro ; Harada, Hiroshi ; Hiraoka, Masahiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6561-470a733d640c7433aaba0916136118853b83483655ab8cf04dbf10a6f6e5ccf03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood vessels</topic><topic>Cancer therapies</topic><topic>Cell Hypoxia</topic><topic>Cytotoxicity</topic><topic>Gene Expression</topic><topic>Genetic Therapy - methods</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Hypoxia-Inducible Factor 1</topic><topic>Ionizing radiation</topic><topic>Medical sciences</topic><topic>Neoplasms - blood supply</topic><topic>Neoplasms - therapy</topic><topic>Phenotypes</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Review</topic><topic>Solid tumors</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kizaka‐Kondoh, Shinae</creatorcontrib><creatorcontrib>Inoue, Masahiro</creatorcontrib><creatorcontrib>Harada, Hiroshi</creatorcontrib><creatorcontrib>Hiraoka, Masahiro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Kizaka‐Kondoh, Shinae</au><au>Inoue, Masahiro</au><au>Harada, Hiroshi</au><au>Hiraoka, Masahiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor hypoxia: A target for selective cancer therapy</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2003-12</date><risdate>2003</risdate><volume>94</volume><issue>12</issue><spage>1021</spage><epage>1028</epage><pages>1021-1028</pages><issn>1347-9032</issn><issn>1349-7006</issn><eissn>1349-7006</eissn><abstract>Tumor hypoxia has been considered to be a potential therapeutic problem because it renders solid tumors more resistant to sparsely ionizing radiation (IR) and chemotherapeutic drugs. Moreover, recent laboratory and clinical data have shown that tumor hypoxia is also associated with a more malignant phenotype and poor survival in patients suffering from various solid tumors. Therefore, selective targeting of hypoxic tumor cells has been explored, and since severe hypoxia (pO2<0.33%, 2.5 mmHg) does not occur in normal tissue, tumor hypoxia could be exploited for therapeutic advantage. However, the following three characteristics of hypoxic tumor regions present obstacles in targeting hypoxic cells. First, it is difficult to deliver a sufficient amount of drug to a region that is remote from blood vessels. Second, one must specifically target hypoxic tumor cells while sparing normal well‐oxygenated tissue from damage. Finally, the severely hypoxic tumor cells to be attacked have often stopped dividing. Therefore, high delivery efficiency, high specificity and selective cytotoxicity are all necessary to target and combat hypoxic tumor cells. The current review describes progress on the biological aspects of tumor hypoxia and provides a compilation of the recent molecular approaches used to target hypoxic tumors. These approaches include our work with a unique hypoxia‐targeting protein drug, TOP3, with which we have sought to address the above three difficulties.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>14662015</pmid><doi>10.1111/j.1349-7006.2003.tb01395.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2003-12, Vol.94 (12), p.1021-1028 |
| issn | 1347-9032 1349-7006 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11160235 |
| source | Wiley Online Library Open Access |
| subjects | Animals Antineoplastic Agents - therapeutic use Biological and medical sciences Blood vessels Cancer therapies Cell Hypoxia Cytotoxicity Gene Expression Genetic Therapy - methods Humans Hypoxia Hypoxia-Inducible Factor 1 Ionizing radiation Medical sciences Neoplasms - blood supply Neoplasms - therapy Phenotypes Recombinant Fusion Proteins - therapeutic use Review Solid tumors Tumor cells Tumors |
| title | Tumor hypoxia: A target for selective cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T04%3A34%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20hypoxia:%20A%20target%20for%20selective%20cancer%20therapy&rft.jtitle=Cancer%20science&rft.au=Kizaka%E2%80%90Kondoh,%20Shinae&rft.date=2003-12&rft.volume=94&rft.issue=12&rft.spage=1021&rft.epage=1028&rft.pages=1021-1028&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/j.1349-7006.2003.tb01395.x&rft_dat=%3Cproquest_24P%3E71439832%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2399782323&rft_id=info:pmid/14662015&rfr_iscdi=true |